spacer
home > ebr > winter 2003 > peptides in metabolic diseases - peptidomics as a comprehensive profiling tool
PUBLICATIONS
European Biopharmaceutical Review

Peptides in Metabolic Diseases - Peptidomics as a Comprehensive Profiling Tool

The genotype represents a blueprint of an organism, which is used in different ways during development, adulthood and disease states. Quantitative changes in the use of genes contribute to the variability of general physiology and pathophysiology. A mutation of a gene qualitatively changes the genotype and thus may determine a predisposition for a disease. However, peptides and proteins define the actual phenotype and may reflect or even cause a pathogenic process. Therefore proteomics is regarded as a pivotal technology in defining the transition from health to disease, describing the current disease status and its progression with time. In this context, it has to be distinguished between technologies addressing proteins in general and those specifically analysing peptides.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Imke Schulte, Metabolic Syndrome Project Research Manager, Hartmut Selle, Biomarker Discovery Project Research Manager, and Peter Schulz-Knappe, CSO and Co-founder of BioVisioN

Having graduated from the University Mьnster in Biochemistry, Imke Schulte worked on molecular and cellular physiology for her doctoral thesis at the Medical School in Hannover. In 2002 she joined BioVisioN as a Project Manager, working in the medical research department with responsibility for projects in the field of the metabolic syndrome.


Hartmut Selle graduated as a Biologist from the University of Hannover in Germany. He worked as a Clinical Research Assistant for the pharmaceutical industry conducting clinical trials on disorders of the CNS, the vascular system and the gastrointestinal tract. In 1999 he joined BioVisioN as a Project Manager and has been involved in a number of projects on biomarker discovery, including Alzheimer's disease.


Peter Schulz-Knappe is one of four founders of BioVisioN. He holds a Medical degree from the University of Heidelberg, and a degree in Cell Biology from the Medical School in Hannover. He has over 20 years experience in peptide chemistry and functional analysis of peptides. As CSO he is responsible for the scientific work in the company.

spacer
Imke Schulte
spacer
spacer
spacer
Hartmut Selle
spacer
spacer
spacer
Peter Schulz-Knappe
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo awarded with the prestigious Cargo Airline of the Year 2019 prize by the global logistics industry

 Maintaining its upward trend, Turkish Cargo was granted with the ‘Cargo Airline of the Year 2019’ award, called as the Oscar of the global logistics industry, by the global air cargo sector readers of the Air Cargo News magazine.
More info >>

White Papers

Backward Thinking

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement